middle.news
Amplia Therapeutics Doses First Patient in Pivotal Pancreatic Cancer Trial
8:28am on Thursday 4th of September, 2025 AEST
•
Healthcare
Read Story
Amplia Therapeutics Doses First Patient in Pivotal Pancreatic Cancer Trial
8:28am on Thursday 4th of September, 2025 AEST
Key Points
First patient dosed in Amplia’s pancreatic cancer trial
Trial combines FAK inhibitor narmafotinib with FOLFIRINOX chemotherapy
Conducted across sites in Australia and the US
Dose escalation phase expected to complete by Q1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE